Moreover, the finding that Blimp1 loss in Tregs and TFR cells promotes CNS autoimmunity may suggest new approaches to manipulation of Treg activity in vivo and provide critical strategies to formulate new or combined therapeutic approaches to MS and other autoimmune disorders. This evidence concerns the gene TFRC and myeloid sarcoma.